Natco Pharma Files Application Seeking Compulsory License For COVID Drug Baricitinib
3 years, 8 months ago

Natco Pharma Files Application Seeking Compulsory License For COVID Drug Baricitinib

Live Law  

Indian generic drug manufacturer Natco Pharma Limited has filed an application before the Controller of Patents seeking compulsory license to produce the drug 'Baricitinib' which is used for treatment of COVID-19.Natco filed application under Section 92 read with 92 of the Patents Act seeking compulsory license to produce 'Baricitinib' at an affordable rate amid the second wave of the. Indian generic drug manufacturer Natco Pharma Limited has filed an application before the Controller of Patents seeking compulsory license to produce the drug 'Baricitinib' which is used for treatment of COVID-19. Natco filed application under Section 92 read with 92 of the Patents Act seeking compulsory license to produce 'Baricitinib' at an affordable rate amid the second wave of the COVID pandemic. Section 92 is a special provision in the Patents Act empowering the Patent Controller to issue compulsory license to any interested person to manufacture a patented drug to meet a public health emergency.

India Indian Covid Drug License Patents Controller Compulsory Files Application Natco Pharma Baricitinib Compulsory License Files Application Seeking Natco Filed  compulsory  patents  drug  license  natco  filed  covid  india  files  application  seeking  pharma  baricitinib

History of this topic

Natco, 9 others chosen to supply COVID-19 drug
2 years, 11 months ago

Natco, 9 others chosen to supply COVID-19 drug

The Hindu  

January 20, 2022 10:45 pm | Updated January 21, 2022 12:52 am IST - HYDERABAD United Nations-backed public health organisation Medicines Patent Pool has signed sublicence agreements with 10 generic drugmakers in India for the manufacturing of COVID-19 antiviral oral drug molnupiravir and supply in 105 low- and-middle-income countries. Natco, Strides, Biophore, SMS Pharmaceuticals, Laurus, Lupin, MSN, Arene Lifesciences, BDR …

Plea In SC Seeks Authorisation For Use Of Remdesivir, Favipiravir and Tocilizumab For Govt. Purposes And/Or Grant Compulsory Licenses For Their Patents
3 years, 8 months ago

Plea In SC Seeks Authorisation For Use Of Remdesivir, Favipiravir and Tocilizumab For Govt. Purposes And/Or Grant Compulsory Licenses For Their Patents

Live Law  

An Application has been filed in the suo moto matter before the Supreme Court pertaining to the COVID-19 crisis in the country seeking directions to issue authorization for using the patents for government purpose and/or notifying grant of Compulsory Licenses under Patents Act for patent covering drugs Remdesivir, Favipiravir and Tocilizumab. Filed by Jan Swasthya Abhiyan of the Drug Price …

Discover Related